MCL1 and cancer: In this way, loss of 4E-BP1 phosphorylation has previously been shown to result in a decrease of Mcl-1 protein expression in various cancer types in vitro and in vivo leading to therapeutic benefit [19, 22] and overexpression of eIF4E led to Mcl-1 expression in our models.